Literature DB >> 3467798

Gene transfer to primary normal and malignant human hemopoietic progenitors using recombinant retroviruses.

D E Hogge, R K Humphries.   

Abstract

To study the feasibility of using retroviruses for gene transfer into human hemopoietic cells, various cell types were exposed to virus carrying the gene for neomycin resistance (neor). In preliminary studies using K562 cells as targets, we found that high viral titer and co-cultivation with viral producer cells rather than incubation in medium exposed to viral producer cells were important variables for achieving high frequencies of G418 resistant (G418r) colonies. The maximum frequency of G418r K562 colonies after co-cultivation with cells producing a neor virus titer of 4 X 10(6) cfu/mL was 60%. When primary human progenitors from normal marrow, fetal liver, or chronic myelogenous leukemia blood were exposed to high titer viral stocks, both with and without helper virus, under conditions optimized for K562 cells, maximum frequencies of G418r colonies were 3% to 16% for granulocyte macrophage progenitors and 2% to 6% for primitive erythroid progenitors. The presence of the neor gene in both G418r K562 and primary hemopoietic colonies was verified by Southern blot. Expression of the neor gene was shown by RNA spot blot. These data demonstrate efficient transfer and expression of the neor gene in both K562 cells and primary human hemopoietic cells from normal and leukemic individuals.

Entities:  

Mesh:

Year:  1987        PMID: 3467798

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Enhancer sequences of a retroviral vector determine expression of a gene in multipotent hematopoietic progenitors and committed erythroid cells.

Authors:  C A Holland; P Anklesaria; M A Sakakeeny; J S Greenberger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

2.  Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease.

Authors:  J K Fink; P H Correll; L K Perry; R O Brady; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

3.  Retroviral gene transfer to primitive normal and leukemic hematopoietic cells using clinically applicable procedures.

Authors:  P F Hughes; J D Thacker; D Hogge; H J Sutherland; T E Thomas; P M Lansdorp; C J Eaves; R K Humphries
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Design of retrovirus vectors for transfer and expression of the human beta-globin gene.

Authors:  A D Miller; M A Bender; E A Harris; M Kaleko; R E Gelinas
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans.

Authors:  W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

6.  Expression of the human beta-globin gene after retroviral transfer into murine erythroleukemia cells and human BFU-E cells.

Authors:  M A Bender; A D Miller; R E Gelinas
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

7.  Introduction of new genetic material into human myeloid leukemic blast stem cells by retroviral infection.

Authors:  L J Smith; S Benchimol
Journal:  Mol Cell Biol       Date:  1988-02       Impact factor: 4.272

8.  Selection of transduced CD34+ progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors.

Authors:  M Migita; J A Medin; R Pawliuk; S Jacobson; J W Nagle; S Anderson; M Amiri; R K Humphries; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

9.  Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer.

Authors:  P W Kantoff; A P Gillio; J R McLachlin; C Bordignon; M A Eglitis; N A Kernan; R C Moen; D B Kohn; S F Yu; E Karson
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

10.  Human cord blood cells as targets for gene transfer: potential use in genetic therapies of severe combined immunodeficiency disease.

Authors:  T Moritz; D C Keller; D A Williams
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.